Current standard therapies to manage DKD recommend drugs controlling blood pressure and hyperglycemia, mainly including renin angiotensin aldosterone system (RAAS) inhibitors, sodium glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide 1 (GLP1) receptor agonist. Here, SLC5A2 is linked to diabetic kidney disease.